Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

I'm sure it is all just coincidence.

Epic won in court and should bypass Pediatric Exclusivity. Supreme Court declined Purdue's appeal sixty days ago. I believe PuraCap could get their generic OxyContin ANDA approval very soon.

I find it intriguing that just as PuraCap is expecting imminent Full Approval of their generic OxyContin ANDA, Nasrat and Doug Plassche have learned how to make commercial batches of bioequivalent generic OxyContin.




http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82907&GoTopage=1&Category=2163&BzID=2258&t=2086&G=939

Elite Pharmaceuticals Reports Positive Topline Results From A Pivotal Bioequivalence Study For A Generic OxyContin®
NORTHVALE, N.J, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study initiated in November 2016.

Nasrat, what are you trying to say by telling us when the study was initiated?





https://www.bna.com/no-high-court-n57982082749/

November 15, 2016
No High Court Review of Purdue OxyContin Patent Invalidity

By Tony Dutra

Nov. 14 — Purdue Pharma L.P. lost its last chance Nov. 14 to use patent protection to stall certain generic versions of its best-selling painkiller, OxyContin.

The U.S. Supreme Court rejected two petitions for review of U.S. Court of Appeals for the Federal Circuit rulings. The appeals court held that three Purdue patents on a less toxic formulation known as low-ABUK oxycodone were invalid as obvious, and that Grünenthal GmbH’s patent on making OxyContin resistant to abuse was not novel. Purdue licenses Grünenthal’s patent.

Amneal Pharmaceuticals LLC, Epic Pharma LLC, Mylan Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc. have announced plans to introduce generic low-ABUK or abuse-resistant oxycodone.